Vaccines targeting drugs of abuse: Is the glass half-empty or half-full?

Nature Reviews Immunology

Volumn 12, Issue 1, 2012, Pages 67-72

  Janda, Kim D ^a   Treweek, Jennifer B ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; AMPHETAMINE; BENZODIAZEPINE; CARBOHYDRATE; CARRIER PROTEIN; CHOLERA TOXIN B SUBUNIT; COCAINE; CYTOKINE; HEMOCYANIN; LIPOSOME; MONOCLONAL ANTIBODY; MORPHINE; NICOTINE; PHENCYCLIDINE; VACCINE;

ANTIGEN BINDING; BACTERIOPHAGE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; DRUG DETOXIFICATION; DRUG OVERDOSE; DRUG TARGETING; EMULSION; FOOD AND DRUG ADMINISTRATION; HEROIN DEPENDENCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; ISOELECTRIC POINT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY; SUBSTANCE-RELATED DISORDERS; VACCINES;

EID: 84655167585     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3130     Document Type: Review

References (60)

1. Stowe, G. N. et al. A vaccine strategy that induces protective immunity against heroin. J. Med. Chem. 54, 5195-5204 (2011).
2. Nelson, A. L., Dhimolea, E. & Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nature Rev. Drug Discov. 9, 767-774 (2010).
3. Anton, B. et al. Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum. Vaccin. 5, 214-229 (2009).
4. Carrera, M. R. et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl Acad. Sci. USA 97, 6202-6206 (2000). (Pubitemid 30367547)
5. Cerny, E. H. & Cerny, T. Vaccines against nicotine. Hum. Vaccin. 5, 200-205 (2009).
6. Haney, M., Gunderson, E. W., Jiang, H., Collins, E. D. & Foltin, R. W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 67, 59-65 (2010).
7. Harvey, B. R. et al. Engineering of recombinant antibody fragments to methamphetamine by anchored periplasmic expression. J. Immunol. Methods 308, 43-52 (2006). (Pubitemid 43107953)
8. Kantak, K. M. et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 148, 251-262 (2000). (Pubitemid 30136732)
9. Keyler, D. E., Roiko, S. A., Earley, C. A., Murtaugh, M. P. & Pentel, P. R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int. Immunopharmacol. 8, 1589-1594 (2008).
10. Keyler, D. E. et al. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose-and affinity-response relationships. Drug Metab. Dispos. 33, 1056-1061 (2005). (Pubitemid 41002789)
11. Lacy, H. M., Gunnell, M. G., Laurenzana, E. M. & Owens, S. M. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int. Immunopharmacol. 8, 1-11 (2008). (Pubitemid 350199094)
12. McClurkan, M. B., Valentine, J. L., Arnold, L. & Owens, S. M. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J. Pharmacol. Exp. Ther. 266, 1439-1445 (1993). (Pubitemid 24175789)
13. McKenzie, K. M. et al. Identification and characterization of single chain anti-cocaine catalytic antibodies. J. Mol. Biol. 365, 722-731 (2007). (Pubitemid 44960359)
14. Owens, S. M. & Mayersohn, M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab. Dispos. 14, 52-58 (1986). (Pubitemid 16152314)
15. Pentel, P. R. et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 65, 191-198 (2000). (Pubitemid 30018012)
16. Peterson, E. C. et al. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther. 322, 30-39 (2007). (Pubitemid 46956367)
17. Peterson, E. C., Laurenzana, E. M., Atchley, W. T., Hendrickson, H. P. & Owens, S. M. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J. Pharmacol. Exp. Ther. 325, 124-133 (2008). (Pubitemid 351439176)
18. Roiko, S. A. et al. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J. Pharmacol. Exp. Ther. 325, 985-993 (2008). (Pubitemid 351724343)
19. Schabacker, D. S., Kirschbaum, K. S. & Segre, M. Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2β anti-idiotypic antibodies. Immunology 100, 48-56 (2000). (Pubitemid 30242881)
20. Treweek, J. B., Roberts, A. J. & Janda, K. D. Immunopharmacotherapeutic manifolds and modulation of cocaine overdose. Pharmacol. Biochem. Behav. 98, 474-484 (2011).
21. Pitas, G., Laurenzana, E. M., Williams, D. K., Owens, S. M. & Gentry, W. B. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab. Dispos. 34, 906-912 (2006). (Pubitemid 43763745)
22. Ohmura, N., Lackie, S. J. & Saiki, H. An immunoassay for small analytes with theoretical detection limits. Anal. Chem. 73, 3392-3399 (2001). (Pubitemid 32880624)
23. Paula, S., Tabet, M. R., Farr, C. D., Norman, A. B. & Ball, W. J. J. Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody. J. Med. Chem. 47, 133-142 (2004). (Pubitemid 38040497)
24. Valentine, J. L., Arnold, L. W. & Owens, S. M. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J. Pharmacol. Exp. Ther. 269, 1079-1085 (1994). (Pubitemid 24204188)
25. Covell, D. G. et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res. 46, 3969-3978 (1986). (Pubitemid 16075893)
26. Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nature Biotech. 23, 1126-1136 (2005). (Pubitemid 41486394)
27. Eddleston, M. & Persson, H. Acute plant poisoning and antitoxin antibodies. J. Toxicol. Clin. Toxicol. 41, 309-315 (2003). (Pubitemid 36676581)
28. Valentine, J. L. & Owens, S. M. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J. Pharmacol. Exp. Ther. 278, 717-724 (1996). (Pubitemid 27167038)
29. Proksch, J. W., Gentry, W. B. & Owens, S. M. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J. Pharmacol. Exp. Ther. 292, 831-837 (2000). (Pubitemid 30136572)
30. Shelver, W. L. et al. Effects of recombinant drug-specific single chain antibody Fv fragment on [3H]-desipramine distribution in rats. Biochem. Pharmacol. 51, 531-537 (1996).
31. Keyler, D. E., Le Couteur, D. G., Pond, S. M., St. Peter, J. V. & Pentel, P. R. Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver. J. Pharmacol. Exp. Ther. 272, 1117-1123 (1995).
32. Butler, V. P. J. et al. Effects of digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. J. Clin. Invest. 59, 345-359 (1977).
33. Scherrmann, J. M. et al. Immunotoxicotherapy: present status and future trends. J. Toxicol. Clin. Toxicol. 27, 1-35 (1989).
34. Bird, R. E. et al. Single-chain antigen-binding proteins. Science 242, 423-426 (1988).
35. Holton, O. D. et al. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. J. Immunol. 139, 3041-3049 (1987).
36. Cornuz, J. et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 3, e2547 (2008).
37. Martell, B. A. et al. Cocaine vaccine for the treament of cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Arch. Gen. Psychiatry 66, 1116-1123 (2009).
38. Glenny, A. T., Pope, C. G., Waddington, H. & Wallace, U. Immunological notes. XXIII. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29, 38-39 (1926).
39. Grun, J. L. & Maurer, P. H. Different T helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses. Cell. Immunol. 121, 134-145 (1989). (Pubitemid 19160191)
40. Leroux-Roels, G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28, C25-C36 (2010).
41. Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P. & Cambier, J. C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304, 1808-1810 (2004). (Pubitemid 38787898)
42. Brewer, J. M. (How) do aluminium adjuvants work? Immunol. Lett. 102, 10-15 (2006). (Pubitemid 41606034)
43. Fox, B. S. et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med. 2, 1129-1132 (1996). (Pubitemid 26338633)
44. Carrera, M. R. et al. Suppression of psychoactive effects of cocaine by active immunization. Nature 378, 727-730 (1995). (Pubitemid 26001945)
45. Tatsis, N. & Ertl, H. C. Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629 (2004). (Pubitemid 39272851)
46. Maurer, P. et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35, 2031-2040 (2005). (Pubitemid 41015042)
47. Hicks, M. J. et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther. 19, 612-619 (2011).
48. Kornberg, A. Ten commandments: lessons from the enzymology of DNA replication J. Bacteriol. 182, 3613-3618 (2000). (Pubitemid 30413008)
49. Carrera, M. R., Ashley, J. A., Wirsching, P., Koob, G. F. & Janda, K. D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl Acad. Sci. USA 98, 1988-1992 (2001). (Pubitemid 32165610)
50. Moreno, A. Y. et al. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol. Pharm. 7, 431-441 (2010).
51. Hatsukami, D. K. et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 89, 392-399 (2011).
52. Lees, A. et al. Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules. Vaccine 12, 1160-1166 (1994). (Pubitemid 24293234)
53. Katsnelson, A. Ethical quagmire awaits vaccine for cocaine addiction. Nature Med. 10, 1007 (2004). (Pubitemid 39424848)
54. Cohen, P. J. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend. 48, 167-174 (1997). (Pubitemid 27526023)
55. National Research Council and Institute of Medicine. New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions (eds Harwood, H. J. & Myers, T. G.) (The National Academies Press, Washington, District of Columbia, 2004).
56. The National Center on Addiction and Substance Abuse (CASA). Shoveling Up II: The Impact of Substance Abuse on Federal, State and Local Budgets [online], http://www.casacolumbia.org/articlefiles/380-ShovelingUpII.pdf (2009).
57. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings [online], http://www.oas.samhsa. gov/NSDUH/2k9NSDUH/2k9Results.htm (2010).
58. Silva, D. G., Cooper, P. D. & Petrovsky, N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol. Cell Biol. 82, 611-616 (2004). (Pubitemid 39563962)
59. Lindblad, E. B., Elhay, M. J., Silva, R., Appelberg, R. & Andersen, P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65, 623-629 (1997). (Pubitemid 27053234)
60. Lindblad, E. B. Aluminium adjuvants-in retrospect and prospect. Vaccine 22, 3658-3668 (2004).